CKI-7 HCl

Modify Date: 2024-01-05 07:58:36

CKI-7 HCl structure	Common Name	CKI-7 HCl
	CAS Number	1177141-67-1	Molecular Weight	358.67200
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₁₁H₁₄Cl₃N₃O₂S	Melting Point	N/A
	MSDS	Chinese USA	Flash Point	N/A
	Symbol	GHS06	Signal Word	Danger

Use of CKI-7 HCl

CKI-7 is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM. CKI-7 is a selective Cdc7 kinase inhibitor. CKI-7 also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 has a much weaker effect on casein kinase II and other protein kinases[1][2][3][4].

Name	N-(2-Aminoethyl)-5-chloroisoquinoline-8-sulfonamide Dihydrochloride
Synonym	More Synonyms

Description	CKI-7 is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM. CKI-7 is a selective Cdc7 kinase inhibitor. CKI-7 also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 has a much weaker effect on casein kinase II and other protein kinases[1][2][3][4].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Metabolic Enzyme/Protease >> SGK Signaling Pathways >> Cell Cycle/DNA Damage >> CDK Signaling Pathways >> Cell Cycle/DNA Damage >> Casein Kinase Signaling Pathways >> MAPK/ERK Pathway >> Ribosomal S6 Kinase (RSK) Signaling Pathways >> Stem Cell/Wnt >> Casein Kinase
Target	CK1:6 μM (IC50) CK1:8.5 μM (Ki) Cdc7 SGK S6K1 MSK1
In Vitro	CKI-7 (0.1-10 μM; 5 days; ES cells) treatment significantly increases the expression of the early neuroectodermal marker Sox1 and the number of cells positive for the neural markers nestin and βIII-tubulin, in a concentration-dependent manner[1]. CKI-7 (5 μM; 5 days; ES cells) treatment suppresses SFEB-induced β-catenin stabilization on day 5, indicating that CKI-7 inhibits Wnt signaling[1]. RT-PCR[1] Cell Line: Mouse ES cells Concentration: 0.1-10 μM Incubation Time: 5 days Result: Significantly increased the expression of the early neuroectodermal marker Sox1 and the number of cells positive for the neural markers nestin and βIII-tubulin, in a concentration-dependent manner. Western Blot Analysis[1] Cell Line: Mouse ES cells Concentration: 5 μM Incubation Time: 5 days Result: Suppressed SFEB-induced β-catenin stabilization on day 5.
In Vivo	In vivo dose-dependent anti-tumor activity of CKI-7 is demonstrated in a SCID-Beige mouse systemic tumor model utilzing a recently isolated Philadelphia chromosome positive acute lymphoblastic leukemia cell line. Standard cell cycle synchronization studies established that exposure to CKI-7 results in cell cycle dependent caspase 3 activation and apoptotic cell death[2].
References	[1]. Osakada F, et al. In vitro differentiation of retinal cells from human pluripotent stem cells by small-molecule induction. J Cell Sci. 2009 Sep 1;122(Pt 17):3169-79. [2]. Mark G. Frattini, et al. Small Molecule Inhibition of Cdc7, a Key Cell Cycle Regulator and Novel Therapeutic Target, Successfully Inhibits Leukemia Cell Growth in Vitro and in Vivo. Blood (2008) 112 (11): 2668. [3]. Chijiwa T, et al. A newly synthesized selective casein kinase I inhibitor, N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide, and affinity purification of casein kinase I from bovine testis. J Biol Chem. 1989 Mar 25;264(9):4924-7. [4]. Rena G, et al. D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. EMBO Rep. 2004 Jan;5(1):60-5.

Molecular Formula	C₁₁H₁₄Cl₃N₃O₂S
Molecular Weight	358.67200
Exact Mass	356.98700
PSA	93.46000
LogP	4.90120
Storage condition	-20°C

CKI-7 HCl MSDS(Chinese)

Symbol	GHS06
Signal Word	Danger
Hazard Statements	H301
Precautionary Statements	P301 + P310
Personal Protective Equipment	Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges
Hazard Codes	T+
RIDADR	UN 2811 6.1 / PGIII
Hazard Class	6.1

An update on metabolic assessment in patients with urinary lithiasis.

World J. Urol. , (2014)

The objective of this study was to evaluate the prevalence of urinary metabolic abnormalities in patients with urolithiasis and their potential risk factors.A total of 905 stone patients were evaluate...

Clinical characteristics and outcome of 467 patients with a clinically recognized eating disorder identified among 52,215 patients with type 1 diabetes: a multicenter german/austrian study.

Diabetes Care , (2014)

To compare clinical characteristics and outcome of type 1 diabetes mellitus (T1DM) between patients with and without a clinically recognized eating disorder (ED).A total of 52,215 T1DM patients aged 8...

Uterine adenomyosis and in vitro fertilization outcome: a systematic review and meta-analysis.

Hum. Reprod. , (2014)

Is adenomyosis associated with IVF/ICSI outcome in terms of clinical pregnancy rate?In a meta-analysis of published data, women with adenomyosis had a 28% reduction in the likelihood of clinical pregn...

N-(2-Aminoethyl)-5-chloroisoquinoline-8-sulphonamide dihydrochloride

CKI-7 dihydrochloride

N-(2-Aminoethyl)-5-chloro-8-isoquinolinesulfonamide dihydrochlori de

DC Chemicals Limited
China
Product Name: CKI-7 dihydrochloride
Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/500mg
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

Dayang Chem (Hangzhou) Co., Ltd.
China
Product Name: N-(2-Aminoethyl)-5-chloroisoquinoline-8-sulfonamide Dihydrochloride
Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
Purity: 98.0%
Stocking Period: Inquiry
Contact: Ms Wang

Get all suppliers and price by the below link:

CKI-7 HCl suppliers

CKI-7 HCl price

CKI-7 HCl

Use of CKI-7 HCl

Names

CKI-7 HCl Biological Activity

Chemical & Physical Properties

MSDS

Safety Information

Articles25

Synonyms